Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.17

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $5.17.

A number of brokerages have recently issued reports on SGMO. Barclays boosted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Wells Fargo & Company dropped their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Jefferies Financial Group dropped their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Finally, StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th.

Institutional Trading of Sangamo Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Sageworth Trust Co purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at about $61,000. Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics by 2,592.3% in the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after purchasing an additional 313,587 shares in the last quarter. Shelton Wealth Management LLC purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at about $29,000. Virtu Financial LLC purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at about $150,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after purchasing an additional 272,123 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

NASDAQ SGMO opened at $1.13 on Friday. The firm has a market cap of $235.77 million, a PE ratio of -1.51 and a beta of 1.29. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The firm’s fifty day moving average is $1.76 and its two-hundred day moving average is $1.33.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same period in the previous year, the business posted ($0.34) earnings per share. Research analysts predict that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.